Basophil granule proteins
AssigneeIncyte Pharmaceuticals, Inc.
InventorsRandy W. Scott, Gerald J. Gleich, Craig G. Wilde
Life of this patent
Estimating the term…
Abstract
Several natural polypeptides (basophil granule proteins, "BGP") derived from the cytoplasmic granules of human basophils, and modified forms thereof, are described. These polypeptides, the DNA which encodes them and antibodies which recognize them, are useful as diagnostics for, and treatments for, pathologies involving inflammatory and IgE-mediated responses, parasitic and helminthic infections, hypersensitivity reactions and certain types of leukocytic leukemias.
Claims2
An injectable composition, comprising:
- a pharmaceutically acceptable excipient;
- and
- a human basophil granule protein in an isolated and purified form, the protein having an N-terminal sequence selected from the group consisting of:
- Asp-Ile-Gly-Pro-Gln-His-Thr-Ser-Arg-Pro-Trp-Gly-Gln-Thr;
- Asp-Val-Lys-Lys-Asp-Met-Glu-Val-Ser-Cys-Pro-Asp-Gly-Tyr-Thr;
- Val-Met-X-Pro-Asp-Ala-Arg-Ser-X-Arg-Pro-Asp-Gly-X-Thr;
- Ala-Ile-Tyr-X-Arg-Ile-Pro-X-X-Ile-Ala-Gly-Glu-Phe-Arg-Tyr-Gly-Thr-Val-Tyr-T yr-Gln-Gly-Ser-Leu;
- Asp-Ile-Pro-Glu-Val-X-Val-X-Leu-Ala-Ala-Asp-Glu-Ser-Leu-Ala-Pro-Lys;
- Tyr-Pro-Gln-Leu-Ala-Ile-Asn;
- and
- Ser-Ile-Gly-Phe-Val-Glu-Val-X-Leu-Val-Leu;
- wherein the N-terminal sequence is determined from Edman degradation fractions taken from human basophil granule proteins and further wherein X is an amino acid residue present at the indicated position, the human basophil granule protein being isolatable from human basophil granules.
A human basophil granule protein in an isolated and purified form, the protein having an N-terminal sequence selected from the group consisting of:
- Asp-Ile-Gly-Pro-Asp-Gln-His-Thr-Ser-Arg-Pro-Trp-Gly-Gln-Thr;
- Asp-Val-Lys-Lys-Asp-Met-Glu-Val-Set-Cys-Pro-Asp-Gly-Tyr-Thr;
- Val-Met-X-Pro-Asp-Ala-Arg-Ser-X-Arg-Pro-Asp-Gly-X-Thr;
- Ala-Ile-Tyr-X-Arg-Ile-Pro-X-X-Ile-Ala-Gly-Glu-Phe-Arg-Tyr-Gly-Thr-Val-Tyr-T yr-Gln-Gly-Set-Leu;
- Asp-Ile-Pro-Glu-Val-X-Val-X-Leu-Ala-Ala-Asp-Glu-Ser-Leu-Ala-Pro-Lys;
- Tyr-Pro-Gln-Leu-Ala-Ile-Asn;
- and
- Ser-Ile-Gly-Phe-Val-Glu-Val-X-Leu-Val-Leu;
- wherein the N-terminal sequence is determined from Edman degradation fractions taken from human basophil granule proteins and further wherein X is an amino acid residue present at the indicated position, the human basophil granule protein being isolatable from human basophil granules.
Dependencies are inferred from the claim text.